Sangamo Therapeutics Shares Outstanding 2006-2021 | SGMO

Sangamo Therapeutics shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Sangamo Therapeutics Annual Shares Outstanding
(Millions of Shares)
2020 134
2019 112
2018 97
2017 78
2016 71
2015 70
2014 67
2013 56
2012 53
2011 51
2010 45
2009 42
2008 41
2007 37
2006 33
2005 26
Sangamo Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 144
2021-03-31 143
2020-12-31 134
2020-09-30 141
2020-06-30 139
2020-03-31 116
2019-12-31 112
2019-09-30 116
2019-06-30 114
2019-03-31 102
2018-12-31 97
2018-09-30 102
2018-06-30 97
2018-03-31 86
2017-12-31 78
2017-09-30 84
2017-06-30 73
2017-03-31 71
2016-12-31 71
2016-09-30 71
2016-06-30 70
2016-03-31 70
2015-12-31 70
2015-09-30 70
2015-06-30 70
2015-03-31 69
2014-12-31 67
2014-09-30 68
2014-06-30 68
2014-03-31 63
2013-12-31 56
2013-09-30 55
2013-06-30 54
2013-03-31 53
2012-12-31 53
2012-09-30 53
2012-06-30 53
2012-03-31 53
2011-12-31 51
2011-09-30 52
2011-06-30 52
2011-03-31 45
2010-12-31 45
2010-09-30 45
2010-06-30 45
2010-03-31 45
2009-12-31 42
2009-09-30 41
2009-06-30 41
2009-03-31 41
2008-12-31 41
2008-09-30 41
2008-06-30 41
2008-03-31 40
2007-12-31 37
2007-09-30 39
2007-06-30 35
2007-03-31 35
2006-12-31 33
2006-09-30 34
2006-06-30 31
2006-03-31 31
2005-12-31 26
2005-09-30 25
2005-06-30 25
2005-03-31 25
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.429B $0.118B
Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71